Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2024-01-08 Investor Presentation
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
Operational restructuring update: "New SoftOx" well equipped to play a central role in the fight against antibiotic resistant infections
Investor Presentation Classification · 99% confidence The document is titled "SoftOx Valuation Guidance" and contains a detailed Table of Contents, Abbreviations, and extensive sections on 'Mandate and Scope of Work', 'Summary Valuation Guidance', and 'Valuation Methodology and Assumptions'. It includes detailed financial projections, sensitivity analyses based on Discounted Cash Flow (DCF) scenarios, and specific assumptions regarding FDA approval probabilities and royalty rates. This structure, focusing on providing an independent assessment of a business segment's value based on future performance projections, strongly indicates an Investor Presentation or a specialized valuation report intended for investors and management strategy discussions. Given the options, 'Investor Presentation' (IP) is the most fitting category for a comprehensive, forward-looking valuation document presented in this format, rather than a standard regulatory filing (like 10-K or IR) or a brief factsheet (FS). The document is clearly a detailed presentation of analysis, not just an announcement of a report (RPA/RNS).
2024-01-08 English
Operational restructuring update: "New SoftOx" well equipped to play a central role in the fight against antibiotic resistant infections
Investor Presentation Classification · 99% confidence The document is titled with a company name ('SoftOx Solutions AS') and contains sections like 'Disclaimer', 'Overview development of SoftOx the next 2 – 3 years', 'Platform technology', 'Wound and Skin care', 'Respiratory care', and 'Exit strategy'. It discusses clinical results, market projections, and future development plans, which are characteristic of an investor-focused presentation. The text explicitly states, 'This Presentation has been produced by SoftOx Solutions AS (the "Company" or "SoftOx"), solely for use at the presentation to investors held by the Company.' This strongly indicates the document is an Investor Presentation (IP). The length (over 21,000 characters) confirms it is a detailed document, not just a brief announcement (ruling out RPA/RNS based on the 'MENU VS MEAL' rule if it were an announcement, but here it is the presentation itself).
2024-01-08 English
Operational restructuring update: "New SoftOx" well equipped to play a central role in the fight against antibiotic resistant infections
Management Reports Classification · 99% confidence The document is an update titled "Operational restructuring update: 'New SoftOx' well equipped to play a central role in the fight against antibiotic resistant infections," dated January 8, 2024. It details significant internal changes, including cost base reduction, outsourcing, R&D progress (Next Generation technology, Inhalation, Wound Care), and future strategic plans, including financing alternatives and the planned separation of the Wound & Skin care business. This content strongly aligns with a management discussion and analysis of recent performance, strategy, and outlook, which is characteristic of a Management Report (MDA). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER). It is too detailed for an RPA or RNS, as it contains substantive operational and strategic information rather than just announcing a report's availability.
2024-01-08 English
SoftOx Solutions AS Third quarter 2023 report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the third quarter of 2023, titled 'Highlights for Q3 2023'. It contains detailed financial statements (Profit and loss, cash flow, balance sheet data), operational updates, and management commentary on the company's financial situation and outlook. Since it covers a period shorter than a full fiscal year and includes substantive financial data, it is classified as an Interim/Quarterly Report. Q3 2023
2023-11-01 English
SoftOx Solutions AS Third quarter 2023 report
Report Publication Announcement Classification · 98% confidence The document text is extremely short (172 characters) and explicitly states: "Please find attached the third quarter 2023 report for SoftOx Solutions AS". This structure—a brief announcement pointing to an attached or linked report—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. Although the content relates to a 'Third quarter 2023 report' (which might suggest IR), the document itself is merely the announcement of publication, not the comprehensive report. If the document were the full report, it would likely be classified as 'IR' (Interim Report). Since it is just the notification of publication, RPA is the correct classification.
2023-11-01 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for future corporate events, specifically mentioning 'Half-yearly Report', 'Annual Report', 'Annual General Meeting', and various 'Quarterly Reports' for the financial year 2023. It is not the report itself, but rather an announcement detailing the schedule of future reports and meetings. This fits the description of a general regulatory announcement or a schedule update. Since there is no specific category for a 'Financial Calendar', and it is a general announcement about future reporting events, the most appropriate fallback is Regulatory Filings (RNS), although it is closely related to scheduling reports (RPA). Given the content is a schedule of reports rather than an announcement that a specific report has just been published, RNS is the best fit as a general regulatory disclosure.
2023-10-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.